Jun 2026 (Q2 FY26) — Aug 13, 2026
HeartBeam Q2 FY26 — Heart Attack Detection Pre-Sub Submitted, Commercial Rollout Underway
Read the full callHeartBeam (BEAT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
HeartBeam earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -5.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$0.44 +2.33% · +$0.01
Performance −75.1% 1Y
1Y: $1.77 on 15 Oct 2025 → $0.44. High $3.44 (16 Dec 2025), low $0.36 (25 Sept 2026).
- Previous close
- $0.43
- 52-week range
- $0.36 – $3.44
- One year
- −74.57%
Overview
- Symbol
- BEAT
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
HeartBeam earnings calls (BEAT)
Financials
What the filings say
Net profit, year on year: −1% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating profit | -5 | -5 | -6 | -5 | -5 | -5 | -5 | -5 |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net profit | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 |
| EPS ($ per share) | -0.19 | — | -0.18 | -0.15 | -0.15 | — | -0.12 | -0.10 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -5 | -9 | -22 | -37 | -56 | -77 |
| Total liabilities | 5 | 1 | 2 | 1 | 2 | 3 |
| Fixed assets | — | — | 0 | 0 | 0 | 1 |
| Total assets | 0 | 14 | 4 | 17 | 3 | 6 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -1 | -3 | -10 | -12 | -14 | -14 |
| Cash from investing | — | — | 0 | -0 | -0 | -1 |
| Cash from financing | 1 | 16 | 0 | 25 | 1 | 17 |
| Net cash flow | 0 | 13 | -10 | 13 | -14 | 2 |
| Capital expenditure | — | — | 0 | -0 | -0 | -1 |
| Free cash flow | — | — | -10 | -12 | -15 | -15 |
Insider filings
18 filings between Dec 17, 2025 and Jul 24, 2026.
Open market
decisions to buy or sellPurchases
$901.0K
8 purchases by 8 insiders
Sales
$1.08M
3 sales by 2 insiders
Compensation
not trading decisions- 7
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| STROME MARK E | $600.0K | $895.0K | Apr 16, 2026 |
| de Urioste George | — | $182.1K | Dec 18, 2025 |
| Elfrink Willem | $150.0K | — | Apr 16, 2026 |
| Ferrari Richard | $46.0K | — | Apr 16, 2026 |
| Cruickshank Tim | $25.0K | — | Apr 16, 2026 |
| Vajdic Branislav | $25.0K | — | Apr 16, 2026 |
| JAFF MICHAEL R | $25.0K | — | Apr 16, 2026 |
| Ortigas-Wedekind Marga | $20.0K | — | Apr 16, 2026 |
Latest filings (22)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 24, 2026 | Persen Kenneth Harry Chief Technology Officer | Award | 105,740 | $0 |
| Jul 24, 2026 | Vajdic Branislav President | Award | 260,870 | $0 |
| Jul 24, 2026 | Cruickshank Tim CFO | Award | 167,760 | $0 |
| Jun 15, 2026 | Vajdic Branislav President | Award | 2,800,000 | $0 |
| Apr 16, 2026 | Ferrari Richard Director | Purchase | 57,500 | $46.0K |
| Apr 16, 2026 | JAFF MICHAEL R Director | Purchase | 31,250 | $25.0K |
| Apr 16, 2026 | Elfrink Willem Director | Purchase | 187,500 | $150.0K |
| Apr 16, 2026 | Cruickshank Tim CFO | Purchase | 31,250 | $25.0K |
| Apr 16, 2026 | STROME MARK E Director | Purchase | 750,000 | $600.0K |
| Apr 16, 2026 | Ortigas-Wedekind Marga Director | Purchase | 25,000 | $20.0K |
| Apr 16, 2026 | ENO Robert Paul President | Purchase | 12,500 | $10.0K |
| Apr 16, 2026 | Vajdic Branislav Director | Purchase | 31,250 | $25.0K |
| Feb 9, 2026 | Nelson Kenneth Warwick III Director | Award | 17,241 | $0 |
| Feb 9, 2026 | JAFF MICHAEL R Director | Award | 20,689 | $0 |
| Feb 9, 2026 | Ferrari Richard Director | Award | 50,000 | $0 |
| Dec 18, 2025 | de Urioste George Director | Sale | 33,185 | $93.9K |
| Dec 17, 2025 | STROME MARK E 10% owner | Sale | 250,000 | $895.0K |
| Dec 17, 2025 | de Urioste George Director | Sale | 23,961 | $88.2K |
| Feb 14, 2025 | Cruickshank Tim CFO | Purchase | 17,647 | $30.0K |
| Feb 14, 2025 | Ferrari Richard Director | Purchase | 29,412 | $50.0K |
| Sep 6, 2024 | de Urioste George Director | Sale | 1,674 | $3.9K |
| Aug 30, 2024 | de Urioste George Director | Sale | 5,500 | $12.7K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for HeartBeam, Inc.
Free account. Everything above stays public.
Write why you follow HeartBeam, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading